T here has been great interest in transcatheter mitral valve replacement (TMVR) as a potential therapy for high-risk patients with severe mitral regurgitation, with several distinct device systems undergoing first-in-man clinical studies. The Intrepid TMVR (Medtronic Inc, Redwood City, CA), designed for transapical delivery, comprises 2 interconnected self-expanding nitinol stents: (1) an inner stent that houses a bovine pericardial tissue trileaflet valve and; (2) an outer ring that fixes to the mitral annulus by radial force in a cork-like effect ( Figure 1 ). 1 The outer fixation ring is designed to conform to the dynamic anatomy of the mitral valve throughout the cardiac cycle, avoiding distortion of the inner stent and valve.
We report an early case of Intrepid TMVR. A 79-yearold male presented with recurrent admissions for heart failure with severe functional mitral regurgitation secondary to posterior leaflet tethering and annular dilatation in the setting of moderate to severe ischemic cardiomyopathy (LV ejection fraction 37%). His comorbidities included severe pulmonary hypertension, type 2 diabetes mellitus, chronic atrial fibrillation, and chronic kidney disease (creatinine clearance 49mL/ min). He was deemed high risk for conventional mitral valve surgery on Interdisciplinary Heart Team assessment (STS mortality risk 7%) and found to be anatomically suitable for TMVR with the Intrepid device.
TMVR was performed under general anesthesia with transesophageal echocardiography (TEE) guidance. Transapical access was obtained via a mini-anterolateral thoracotomy with placement of a 33Fr apical introducer sheath. The 46 mm Intrepid valve was then deployed under rapid ventricular pacing. 2 The delivery sheath was removed with systolic blood pressure less than 100mmHg and hemostasis achieved with direct closure. 3 Unlike other TMVR systems, the Intrepid valve does not require rotational alignment nor capturing of the native mitral valve leaflets. 4 A good hemodynamic result was achieved with trivial paravalvular leak and no significant left ventricular outflow tract encroachment (Figure 2 The patient made a robust recovery. At 3 months post intervention, his functional status had significantly improved from NYHA class III to class II dyspnea, corresponding to an increase in his 6-minute walk distance from 140 m to 300 m. The patient suffered a right middle cerebral artery territory embolic infarct at 4 months in the context of warfarin cessation for a dental procedure; he subsequently made a full neurological recovery post urgent embolectomy. TEE did not show intracardiac thrombus. At 6 months he remained functionally independent, with transthoracic echocardiography (TTE) reconfirming appropriate valve function (Movie II in the Data Supplement).
The Intrepid TMVR uses a novel new design to address severe mitral regurgitation in high-risk patients.
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